Microsaic Systems plc

Description

Founded in 2001 to develop miniaturised MS instruments based on Micro-Electro-Mechanical Systems (MEMS) technology, Microsaic System Plc is a UK-Based leading high technology business, which is engaged in developing point-of-need mass spectrometers for Pharmaceutical and biopharmaceutical sectors to enhance the efficiency of chemical and biological workflows. The company offers a range of MiD mass detectors products that are developed to combine harmoniously with various third-party OEM equipment providers, or to be standalone. The company’s shares are traded on the Alternative Investment Market of the London Stock Exchange since 2011 as LON: MSYS.

The company’s technology includes chip-based MS technology, small Molecule applications, Biopharma Applications and Integrated Software. The company’s patented chip-based Mass Spectrometry (MS) technology enables point-of-need for analytical detection and characterization which helps users to make decisions to optimize, adjust and control processes in real-time and offers processing and manufacturing agility. Its Small Molecule applications accelerates discovery by upgrading the current detection method to point-of-need mass spectrometry (MS). The Biopharma applications are essential for an efficient Quality-by-Design (QbD) strategy for detailed product and process information at the point-of-need and its integrated software is easy to use mass spectrometry software, which offers full control of sample method, data acquisition and the analysis of the user’s samples.

The company offers a range of products that includes The MiD Platform, MiDas automated sampling and ProteinID. The MiD Platform offers Mass spectrometry (MS) detection solution backed by its miniaturized chip-based technology that allow user to make quick decisions. Further the MiD platform offers 4500 MiD with three main patented chip-based technologies; vac-chip, ion chip, and spraychip.

MiDas Automated sampling optimizes productivity with its portable mass spectrometry that delivers automated sampling, dilution, and injection for direct mass spectrometer analysis. The ProteinID allow users to mass ID protein by simultaneously monitoring and controlling bioprocessing. The company also aims to maintain long-term relationships with OEMs in small molecule and bioprocessing applications. The key distributors of the company are Amedis in Slovakia, iChrom Solutions in North America, Rightek Co.,Ltd in Taiwan and S.T. Japan Inc in Japan.

The company changed its strategy in the early January and in March 2021, it entered into commercial agreement with DeepVerge plc to deploy its product and services internationally in applications such as water monitoring of chemicals and pathogens.

Then in May 2021, it started shipments to its new Chinese partners with a motive to obtain a medical license in China for real-time therapeutic monitoring of drugs with commercialisation expected in 2022 and also collaborated with Swansea University with a motive to combine real-time monitoring of environmental water using AI in determining the link between environmental chemical pollution and human health.